Evidence map›Paper›PMID 39058590›Full record

ArticleCell reports2024

Identification of the main barriers to Ku accumulation in chromatin.

Madeleine Bossaert, Andrew T Moreno, Antonio Peixoto, Marie-Jeanne Pillaire, Pauline Chanut, Philippe Frit, Patrick Calsou, Joseph J Loparo, Sébastien Britton

Abstract read
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Madeleine BossaertInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018.
Andrew T MorenoDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Antonio PeixotoInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018.
Marie-Jeanne PillaireInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018.
Pauline ChanutInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018.
Philippe FritInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018.
Patrick CalsouInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018. Electronic address: patrick.calsou@ipbs.fr.
Joseph J LoparoDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: joseph_loparo@hms.harvard.edu.
Sébastien BrittonInstitut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, France; Equipe Labéllisée la Ligue contre le Cancer 2018. Electronic address: sebastien.britton@ipbs.fr.

Funding

Visualizing DNA break repair: single-molecule studies of non-homologous end joiningR01GM115487 · NIGMS · HARVARD MEDICAL SCHOOL · PI LOPARO, JOSEPH J. · 2015 to 2024
$3.1M
NIGMS NIH HHS R01 GM115487
6 · The paper itself

Abstract

Repair of DNA double-strand breaks by the non-homologous end-joining pathway is initiated by the binding of Ku to DNA ends. Multiple Ku proteins load onto linear DNAs in vitro. However, in cells, Ku loading is limited to ∼1-2 molecules per DNA end. The mechanisms enforcing this limit are currently unclear. Here, we show that the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs), but not its protein kinase activity, is required to prevent excessive Ku entry into chromatin. Ku accumulation is further restricted by two mechanisms: a neddylation/FBXL12-dependent process that actively removes loaded Ku molecules throughout the cell cycle and a CtIP/ATM-dependent mechanism that operates in S phase. Finally, we demonstrate that the misregulation of Ku loading leads to impaired transcription in the vicinity of DNA ends. Together, our data shed light on the multiple mechanisms operating to prevent Ku from invading chromatin and interfering with other DNA transactions.

Indexed as

ChromatinDNA-Activated Protein KinaseKu AutoantigenAtaxia Telangiectasia Mutated ProteinsDNA-Binding ProteinsHumansAtaxia Telangiectasia Mutated ProteinsChromatinDNA-Activated Protein KinaseDNA-Binding ProteinsKu AutoantigenATMCP: Molecular biologyCtIPDNA end resectionDNA-PKDNA-PKcsDNA repairFBXL12KuMRNneddylationNHEJXenopus

Identifiers

PMID39058590
PMCPMC11411529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.